|
1
|
Ritter J and Bielack SS: Osteosarcoma. Ann
Oncol. 21 Suppl 7:vii320–vii325. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Eftekhari F: Imaging assessment of
osteosarcoma in childhood and adolescence: Diagnosis, staging, and
evaluating response to chemotherapy. Cancer Treat Res. 152:33–62.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Luetke A, Meyers PA, Lewis I and Juergens
H: Osteosarcoma treatment-where do we stand? A state of the art
review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Anninga JK, Gelderblom H, Fiocco M, Kroe
JR, Taminiau AH, Hogendoorn PC and Egeler RM: Chemotherapeutic
adjuvant treatment for osteosarcoma: Where do we stand? Eur J
Cancer. 47:2431–2445. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Anderson ME: Update on survival in
osteosarcoma. Orthop Clin North Am. 47:283–292. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
van Schie R, Hagleitner M, Hoogerbrugge P,
Flucke U, Schreuder H and Loo Te M: Overall survival trends in
pediatric osteosarcoma patients over the past three decades. J Clin
Oncol. 27:100412009.
|
|
7
|
Nobis P, Zibirre R, Meyer G, Kühne J,
Warnecke G and Koch G: Production of a monoclonal antibody against
an epitope on HeLa cells that is the functional poliovirus binding
site. J Gen Virol. 66:2563–2569. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mendelsohn CL, Wimmer E and Racaniello VR:
Cellular receptor for poliovirus: Molecular cloning, nucleotide
sequence, and expression of a new member of the immunoglobulin
superfamily. Cell. 56:855–865. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takai Y, Irie K, Shimizu K, Sakisaka T and
Ikeda W: Nectins and nectin-like molecules: Roles in cell adhesion,
migration, and polarization. Cancer Sci. 94:655–667. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ogita H, Ikeda W and Takai Y: Roles of
cell adhesion molecules nectin and nectin-like molecule-5 in the
regulation of cell movement and proliferation. J Microsc.
231:455–465. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bottino C, Castriconi R, Pende D, Rivera
P, Nanni M, Carnemolla B, Cantoni C, Grassi J, Marcenaro S, Reymond
N, et al: Identification of PVR (CD155) and Nectin-2 (CD112) as
cell surface ligands for the human DNAM-1 (CD226) activating
molecule. J Exp Med. 198:557–567. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Atsumi S, Matsumine A, Toyoda H, Niimi R,
Iino T and Sudo A: Prognostic significance of CD155 mRNA expression
in soft tissue sarcomas. Oncol Lett. 5:1771–1776. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Atsumi S, Matsumine A, Toyoda H, Niimi R,
Iino T, Nakamura T, Matsubara T, Asanuma K, Komada Y, Uchida A and
Sudo A: Oncolytic virotherapy for human bone and soft tissue
sarcomas using live attenuated poliovirus. Int J Oncol. 41:893–902.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Masson D, Jarry A, Baury B, Blanchardie P,
Laboisse C, Lustenberger P and Denis MG: Overexpression of the
CD155 gene in human colorectal carcinoma. Gut. 49:236–240. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nakai R, Maniwa Y, Tanaka Y, Nishio W,
Yoshimura M, Okita Y, Ohbayashi C, Satoh N, Ogita H, Takai Y and
Hayashi Y: Overexpression of Necl-5 correlates with unfavorable
prognosis in patients with lung adenocarcinoma. Cancer Sci.
101:1326–1330. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chan CJ, Andrews DM, McLaughlin NM, Yagita
H, Gilfillan S, Colonna M and Smyth MJ: DNAM-1/CD155 interactions
promote cytokine and NK cell-mediated suppression of poorly
immunogenic melanoma metastases. J Immunol. 184:902–911. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ochiai H, Moore SA, Archer GE, Okamura T,
Chewning TA, Marks JR, Sampson JH and Gromeier M: Treatment of
intracerebral neoplasia and neoplastic meningitis with regional
delivery of oncolytic recombinant poliovirus. Clin Cancer Res.
10:4831–4838. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Castriconi R, Dondero A, Corrias MV,
Lanino E, Pende D, Moretta L, Bottino C and Moretta A: Natural
killer cell-mediated killing of freshly isolated neuroblastoma
cells: Critical role of DNAX accessory molecule-1-poliovirus
receptor interaction. Cancer Res. 64:9180–9184. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sloan KE, Eustace BK, Stewart JK,
Zehetmeier C, Torella C, Simeone M, Roy JE, Unger C, Louis DN, Ilag
LL and Jay DG: CD155/PVR plays a key role in cell motility during
tumor cell invasion and migration. BMC Cancer. 4:732004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sloan KE, Stewart JK, Treloar AF, Matthews
RT and Jay DG: CD155/PVR enhances glioma cell dispersal by
regulating adhesion signaling and focal adhesion dynamics. Cancer
Res. 65:10930–10937. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Enloe BM and Jay DG: Inhibition of Necl-5
(CD155/PVR) reduces glioblastoma dispersal and decreases MMP-2
expression and activity. J Neurooncol. 102:225–235. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Feng S, Shi X, Ren KE, Wu S and Sun X:
Focal adhesion kinase is involved in the migration of human
osteosarcoma cells. Oncol Lett. 9:2670–2674. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kager L, Zoubek A, Pötschger U, Kastner U,
Flege S, Kempf-Bielack B, Branscheid D, Kotz R, Salzer-Kuntschik M,
Winkelmann W, et al: Primary metastatic osteosarcoma: Presentation
and outcome of patients treated on neoadjuvant cooperative
osteosarcoma study group protocols. J Clin Oncol. 21:2011–2018.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bielack SS, Kempf-Bielack B, Branscheid D,
Carrle D, Friedel G, Helmke K, Kevric M, Jundt G, Kühne T, Maas R,
et al: Second and subsequent recurrences of osteosarcoma:
Presentation, treatment, and outcomes of 249 consecutive
cooperative osteosarcoma study group patients. J Clin Oncol.
27:557–565. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Collins M, Wilhelm M, Conyers R, Herschtal
A, Whelan J, Bielack S, Kager L, Kühne T, Sydes M, Gelderblom H, et
al: Benefits and adverse events in younger versus older patients
receiving neoadjuvant chemotherapy for osteosarcoma: Findings from
a meta-analysis. J Clin Oncol. 31:2303–2312. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Petrilli AS, de Camargo B, Filho Odone V,
Lustosa D, Borsato ML, Calheiros LM, Brunetto AL, Barreto JH and
Ferraro AA: Fifteen years experience of the Brazilian osteosarcoma
treatment group (BOTG). J Clin Oncol. 27 15 Suppl:S100392009.
|
|
27
|
Nishiwada S, Sho M, Yasuda S, Shimada K,
Yamato I, Akahori T, Kinoshita S, Nagai M, Konishi N and Nakajima
Y: Clinical significance of CD155 expression in human pancreatic
cancer. Anticancer Res. 35:2287–2297. 2015.PubMed/NCBI
|
|
28
|
Qu P, Huang X, Zhou X, Lü Z, Liu F, Shi Z,
Lü L, Wu Y and Chen Y: Loss of CD155 expression predicts poor
prognosis in hepatocellular carcinoma. Histopathology. 66:706–714.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Valastyan S and Weinberg RA: Tumor
metastasis: Molecular insights and evolving paradigms. Cell.
147:275–292. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Steeg PS: Tumor metastasis: Mechanistic
insights and clinical challenges. Nat Med. 12:895–904. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wan L, Pantel K and Kang Y: Tumor
metastasis: Moving new biological insights into the clinic. Nat
Med. 19:1450–1464. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bravo-Cordero JJ, Hodgson L and Condeelis
J: Directed cell invasion and migration during metastasis. Curr
Opin Cell Biol. 24:277–283. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Entschladen F, Drell TL IV, Lang K, Joseph
J and Zaenker KS: Tumour-cell migration, invasion, and metastasis:
Navigation by neurotransmitters. Lancet Oncol. 5:254–258. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Le Dévédec SE, Yan K, de Bont H, Ghotra V,
Truong H, Danen EH, Verbeek F and van de Water B: Systems
microscopy approaches to understand cancer cell migration and
metastasis. Cell Mol Life Sci. 67:3219–3240. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Baumann K: Cell adhesion: FAK or talin:
Who goes first? Nat Rev Mol Cell Biol. 13:1382012.PubMed/NCBI
|
|
36
|
Lee S, Qiao J, Paul P, O'Connor KL, Evers
MB and Chung DH: FAK is a critical regulator of neuroblastoma liver
metastasis. Oncotarget. 3:1576–1587. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Golubovskaya VM, Conway-Dorsey K, Edmiston
SN, Tse CK, Lark AA, Livasy CA, Moore D, Millikan RC and Cance WG:
FAK overexpression and p53 mutations are highly correlated in human
breast cancer. Int J Cancer. 125:1735–1738. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Golubovskaya VM, Finch R, Kweh F, Massoll
NA, Campbell-Thompson M, Wallace MR and Cance WG: p53 regulates FAK
expression in human tumor cells. Mol Carcinog. 47:373–382. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Oda T, Ohka S and Nomoto A: Ligand
stimulation of CD155alpha inhibits cell adhesion and enhances cell
migration in fibroblasts. Biochem Biophys Res Commun.
319:1253–1264. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zheng Q, Wang B, Gao J, Xin N, Wang W,
Song X, Shao Y and Zhao C: CD155 knockdown promotes apoptosis via
AKT/Bcl-2/Bax in colon cancer cells. J Cell Mol Med. Aug
16–2017.(Epub ahead of print).
|
|
41
|
Tane S, Maniwa Y, Hokka D, Tauchi S,
Nishio W, Okita Y and Yoshimura M: The role of Necl-5 in the
invasive activity of lung adenocarcinoma. Exp Mol Pathol.
94:330–335. 2013. View Article : Google Scholar : PubMed/NCBI
|
